Santa Clara, CA 10/13/08—Affymetrix has announced that it expects third-quarter revenues to be approximately $75 million, compared to $95.0 million last year. Analysts had forecasted revenues of $90.1 million, according to Thomson Financial. The company does not provide revenue guidance on a quarterly basis. Affymetrix attributed the shortfall to greater competition for research funding and […]
Donations to charities and other nonprofit institutions that fund medical research could be at risk due to the economic crisis. According to the Center on Philanthropy at the University of Indiana, the level of donations made to charities correlates with the fortunes of the stock markets, but any effects from the current crisis would not […]
French biotechnology companies have 73 products in early-stage development and 98 drugs in clinical development, according to France Biotech. Ten drugs are awaiting market approval and four are on the market. Despite economic conditions and a weak IPO market, France Biotech expects French biotech firms to be able to obtain funding through alliances or mergers […]
Carlsbad, CA 10/9/08; 10/15/08—Invitrogen announced it has amended the terms of its merger agreement with Applied Biosystems (ABI). To allow the companies’ stockholders to consider the amendment, the meetings to vote on the merger will take place October 28, instead of October 16. The amendment eliminates the requirement that the parties receive certain opinions regarding […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
